Expert Interview
A discussion of Replimune cemiplimab and the potential of RP1 in combination as a treatment for Cutaneous squamous cell carcinoma (cSCC)
Ticker(s): REPL, REGNInstitution: MD Anderson
- Professor in the departments of Dermatology and Head and Neck at The University of Texas MD Anderson Cancer Center with a specialty in Mohs surgery and cutaneous oncology.
- Global study PI, steering committee chair, and consultant for multiple clinical trials in basal and squamous cell carcinoma including trials of hedgehog inhibitors, checkpoint inhibitors and genetically modified oncolytic viruses.
- Lead U.S. enroller and first author in publications for the trials bringing cemiplimab, and hedgehog inhibitors to FDA approval.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
